Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$2.38
-0.4%
$2.32
$0.80
$3.42
$97.78M-0.8971,824 shs16,432 shs
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
$6.37
$0.38
$1.24
$26.05M0.91522,308 shs466,373 shs
Equillium, Inc. stock logo
EQ
Equillium
$1.91
+9.1%
$0.85
$0.27
$2.35
$113.65M1.5815.65 million shs7.30 million shs
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
$1.32
-3.6%
$0.98
$0.62
$7.04
$110.96MN/A7.05 million shs759,082 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-0.42%-4.80%-11.85%+120.37%+26.60%
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
0.00%0.00%0.00%0.00%0.00%
Equillium, Inc. stock logo
EQ
Equillium
+9.14%+9.77%+199.61%+402.63%+92.72%
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
-3.65%+7.32%+62.94%+131,999,900.00%+131,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$2.38
-0.4%
$2.32
$0.80
$3.42
$97.78M-0.8971,824 shs16,432 shs
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
$6.37
$0.38
$1.24
$26.05M0.91522,308 shs466,373 shs
Equillium, Inc. stock logo
EQ
Equillium
$1.91
+9.1%
$0.85
$0.27
$2.35
$113.65M1.5815.65 million shs7.30 million shs
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
$1.32
-3.6%
$0.98
$0.62
$7.04
$110.96MN/A7.05 million shs759,082 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-0.42%-4.80%-11.85%+120.37%+26.60%
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
0.00%0.00%0.00%0.00%0.00%
Equillium, Inc. stock logo
EQ
Equillium
+9.14%+9.77%+199.61%+402.63%+92.72%
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
-3.65%+7.32%+62.94%+131,999,900.00%+131,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.50
Moderate Buy$5.50131.09% Upside
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
0.00
N/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
2.00
Hold$1.00-47.64% Downside
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CLBS, EQ, WGRX, and ANEB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/23/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.15 per shareN/A
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/A$1.54 per shareN/A
Equillium, Inc. stock logo
EQ
Equillium
$41.10M2.77N/AN/A$0.54 per share3.54
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
$18.13M6.12N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.20M-$0.26N/AN/AN/A-90.11%-84.53%9/24/2025 (Estimated)
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/A
Equillium, Inc. stock logo
EQ
Equillium
-$8.07M-$0.56N/AN/AN/A-19.62%-139.56%-90.56%11/12/2025 (Estimated)
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
-$6.86MN/A0.00N/AN/AN/AN/AN/A

Latest CLBS, EQ, WGRX, and ANEB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/24/2025Q4 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.05N/AN/AN/AN/AN/A
8/19/2025Q2 2025
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
N/A-$0.11N/A-$0.11N/A$7.79 million
8/14/2025Q2 2025
Equillium, Inc. stock logo
EQ
Equillium
-$0.14-$0.16-$0.02-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
25.29
25.29
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/A
22.33
22.33
Equillium, Inc. stock logo
EQ
Equillium
N/A
1.65
1.65
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
11.16
0.32
0.11

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
15.57%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
N/A

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
2.20%
Equillium, Inc. stock logo
EQ
Equillium
31.60%
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
441.08 million7.97 millionNot Optionable
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
2760.58 million59.25 millionOptionable
Equillium, Inc. stock logo
EQ
Equillium
4059.50 million40.70 millionNot Optionable
Wellgistics Health, Inc. stock logo
WGRX
Wellgistics Health
3184.06 millionN/AN/A

Recent News About These Companies

Wellgistics Health, Inc. to Present at September Investor Conferences
Wellgistics Health Converts $8.1M Debt to Equity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.38 -0.01 (-0.42%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.39 +0.01 (+0.46%)
As of 09/5/2025 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Caladrius Biosciences stock logo

Caladrius Biosciences NASDAQ:CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Equillium stock logo

Equillium NASDAQ:EQ

$1.91 +0.16 (+9.14%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.94 +0.03 (+1.62%)
As of 09/5/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Wellgistics Health stock logo

Wellgistics Health NASDAQ:WGRX

$1.32 -0.05 (-3.65%)
As of 09/5/2025 04:00 PM Eastern

Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL.